...
首页> 外文期刊>Acta Obstetricia et Gynecologica Scandinavica: Official Publication of the Nordisk Forening for Obstetrik och Gynekologi >The efficacy of HPV 16/18 vaccines on sexually active 18-23 year old women and the impact of HPV vaccination on organized cervical cancer screening.
【24h】

The efficacy of HPV 16/18 vaccines on sexually active 18-23 year old women and the impact of HPV vaccination on organized cervical cancer screening.

机译:HPV 16/18疫苗对有性行为的18-23岁女性的功效以及HPV疫苗接种对有组织的宫颈癌筛查的影响。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE: Evaluate the efficacy of catch-up HPV vaccination in sexually active young women and the potential impact of HPV vaccines on the practice of organized screening. SAMPLE: (1) Women enrolled in the Future II study and (2) from a separate population-based study in Iceland. METHODS: (1) Analysis of cytological and histological results and colposcopic examinations among 710 women, aged 18-23, with less than five sexual partners, irrespectively of baseline HPV status at enrolment. (2) The impact on screening practice as determined by evaluating the distribution of 12 oncogenic HPV types in 582 cervical intraepithelial lesions (CIN 2-3) and cancer cases. MAIN OUTCOME MEASURES: (1) Distribution of evaluated parameters according to age at enrolment. (2) Age distribution of four HPV groups, within age classes and HPV groups: mean time to development of lesions, mean time to development of CIN 2-3+, cumulative frequency for CIN 2-3+ lesions after the last normal smear. RESULTS: (1) After an average 52 months of post-enrolment follow-up, significant reductions in all evaluated parameters were observed in women aged 18-19 at enrolment. (2) Among women <25 years, the proportion of cases with only HPV 16/18 was significantly lower and the proportion containing HPV16/18 plus > or =1 out of 10 non-vaccine HPV types (31/33/45/52/58/35/39/51/56/59) was higher than at age 25-49. The proportion of cases containing only the non-vaccine types was the same within all age groups. Cases with HPV 16/18 and some non-vaccine types decreased significantly with age and accumulated more slowly after the last negative smear. CONCLUSIONS: Catch-up vaccination of younger women should be considered in the context of sexual practices and the effects of prevalent disease on observed vaccine efficacy. Current data do not support a change in the lower age limit or screening intervals for women.
机译:目的:评估在性活跃的年轻女性中补充HPV疫苗的效果以及HPV疫苗对有组织筛查实践的潜在影响。示例:(1)妇女参加了Future II研究,(2)来自冰岛另一项基于人群的研究。方法:(1)分析710例年龄在18-23岁,少于五个性伴侣的女性的细胞学和组织学结果以及阴道镜检查结果,与入选时的基线HPV状况无关。 (2)通过评估582种宫颈上皮内病变(CIN 2-3)和癌症病例中12种致癌HPV类型的分布所确定的对筛查实践的影响。主要观察指标:(1)根据入学年龄评估参量的分布。 (2)在年龄组和HPV组内的四个HPV组的年龄分布:平均病变发展时间,平均CIN 2-3 +发展时间,最后一次正常涂片后CIN 2-3 +病变的累积频率。结果:(1)入组后平均随访52个月,入组时18-19岁女性的所有评估参数均明显降低。 (2)在25岁以下的女性中,只有HPV 16/18的病例比例显着降低,并且在10种非疫苗HPV类型中,HPV16 / 18 plus>或= 1的比例(31/33/45/52 / 58/35/39/51/56/59)高于25-49岁。在所有年龄组中,仅包含非疫苗类型的病例比例是相同的。 HPV 16/18和某些非疫苗类型的病例随着年龄的增长而显着下降,并且在上次阴性涂片后积累得更加缓慢。结论:应在性行为和流行病对观察到的疫苗功效的影响的背景下考虑对年轻妇女进行补种疫苗接种。当前数据不支持女性下限或筛查间隔的改变。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号